Scrip Asia 100 - GSK takes the flexible approach to Asian growth
This article was originally published in Scrip
GlaxoSmithKline's approach to growing its business across the Asia-Pacific region recognises the need for distinct strategies tailored to each national market. This may involve a blend of price cuts, regional co-promotion partnerships and targeted M&A deals. The company also realises that innovation can come from any source, Marc Dunoyer tells Ian Haydock in an exclusive one-on-one interview.
You may also be interested in...
Positive clinical results pave path forward for Japanese firm’s potential istradefylline successor.
Curon thinks tenalisib can offer a differentiated and safe new therapy for hematologic cancers such as multiple forms of lymphoma. Axis and PharmaEssentia team up on TCR therapy R&D in Taiwan.
Recent moves show Chinese biotech firms are increasingly looking to go global by recruiting world-class development talent, and J&J names new APAC pharma head.